文献速递细菌感染、耐药与抗菌药物

SOAR 2018-21 科威特与阿联酋抗生素耐药性调查:基于CLSI、EUCAST及PK/PD折点

Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Kuwait and the United Arab Emirates: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

该研究测定了2018-21年科威特和阿联酋社区获得性呼吸道感染中肺炎链球菌与流感嗜血杆菌的抗生素敏感性。采用CLSI微量肉汤稀释法测定MIC,并用CLSI和EUCAST折点解读。结果显示肺炎链球菌对氟喹诺酮类、阿莫西林/克拉维酸等敏感性较高,而对口服/低剂量青霉素、大环内酯类等敏感性较低;流感嗜血杆菌除复方磺胺甲噁唑外敏感性一般>80%。

要点

  • 肺炎链球菌对氟喹诺酮类敏感性>98%,对口服/低剂量青霉素仅20%-27%
  • 流感嗜血杆菌产β-内酰胺酶率科威特17.7%、阿联酋8.8%
  • 流感嗜血杆菌对复方磺胺甲噁唑敏感性仅47%-56%

核心结论

  • 肺炎链球菌对氟喹诺酮类、阿莫西林及阿莫西林/克拉维酸、头孢曲松和头孢噻肟敏感性较高,对口服/低剂量青霉素、大环内酯类、四环素类和复方磺胺甲噁唑敏感性较低。
  • 流感嗜血杆菌除复方磺胺甲噁唑外,总体敏感性一般>80%。

研究设计与样本

  • 研究收集2018-21年科威特和阿联酋社区获得性呼吸道感染患者的肺炎链球菌和流感嗜血杆菌分离株。
  • 采用CLSI微量肉汤稀释法测定MIC,并用CLSI和EUCAST折点解读敏感性。

主要发现

  • 科威特收集肺炎链球菌49株、流感嗜血杆菌79株;阿联酋收集肺炎链球菌49株、流感嗜血杆菌34株。
  • 按CLSI口服/EUCAST低剂量折点,肺炎链球菌对青霉素敏感率阿联酋26.5%、科威特20.4%;按CLSI静脉/EUCAST高剂量折点,敏感率分别为95.9%和85.7%。
  • 肺炎链球菌对头孢曲松、阿莫西林/克拉维酸、阿莫西林和头孢噻肟的敏感性(CLSI)为73.5%-93.9%,对氟喹诺酮类(CLSI/EUCAST高剂量)敏感性≥98.0%。
  • 流感嗜血杆菌产β-内酰胺酶率科威特17.7%、阿联酋8.8%;对阿莫西林/克拉维酸敏感性(CLSI)科威特81.0%、阿联酋97.1%。
  • 流感嗜血杆菌对左氧氟沙星和莫西沙星敏感性(CLSI)阿联酋分别为88.2%和82.4%,科威特均为98.7%;除氨苄西林(科威特81.0%)和复方磺胺甲噁唑(阿联酋47.1%、科威特55.7%)外,敏感性(CLSI)总体>91.2%。

关键数值与推荐

  • 肺炎链球菌对氟喹诺酮类敏感性>98%,对阿莫西林和阿莫西林/克拉维酸敏感性>79%-94%,对头孢曲松和头孢噻肟敏感性>73%-94%。
  • 肺炎链球菌对口服/低剂量青霉素敏感性20%-27%,对大环内酯类33%-51%,对四环素类53%-59%,对复方磺胺甲噁唑33%-61%。
  • 流感嗜血杆菌对复方磺胺甲噁唑敏感性47%-56%,其余药物敏感性一般>80%。

临床怎么用

  • 在科威特和阿联酋经验性治疗社区获得性呼吸道感染时,应参考当地耐药监测数据选择抗生素。
  • 肺炎链球菌经验性治疗可优先考虑氟喹诺酮类、阿莫西林/克拉维酸或第三代头孢菌素,避免单用口服青霉素或大环内酯类。
  • 流感嗜血杆菌治疗应避免单用复方磺胺甲噁唑,并根据β-内酰胺酶携带情况考虑含酶抑制剂复方。

局限性

  • 研究仅纳入科威特和阿联酋2018-21年的分离株,样本量有限,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine antibiotic susceptibility of Streptococcus pneumoniae and Haemophilus influenzae from community-acquired respiratory tract infections in Kuwait and United Arab Emirates (UAE), collected in 2018-21. METHODS: MICs determined by CLSI broth microdilution; susceptibility data interpreted using CLSI and EUCAST breakpoints. RESULTS: A total of 49 S. pneumoniae and 79 H. influenzae and 49 S. pneumoniae and 34 H. influenzae were collected from Kuwait and UAE, respectively. Of the pneumococci, 26.5% (UAE) and 20.4% (Kuwait) were penicillin susceptible by CLSI oral/EUCAST low-dose breakpoints; by CLSI intravenous/EUCAST high-dose administration, 95.9% (UAE) and 85.7% (Kuwait) were susceptible. Similar susceptibility was observed to ceftriaxone, amoxicillin/clavulanic acid, amoxicillin and cefotaxime (CLSI: 73.5%-93.9%) but lower to other cephalosporins, tetracyclines, macrolides and trimethoprim/sulfamethoxazole. Fluoroquinolones were ≥98.0% susceptible (CLSI/EUCAST high-dose). Compared with CLSI, activity was similar by EUCAST high-dose or pharmacokinetic/pharmacodynamic (PK/PD) breakpoints with few exceptions. Of the H. influenzae isolates, 17.7% (Kuwait) and 8.8% (UAE) carried β-lactamases. Significant differences in H. influenzae susceptibility (CLSI) were found for amoxicillin/clavulanic acid (81.0% Kuwait/97.1% UAE) and fluoroquinolones (UAE: levofloxacin 88.2%, moxifloxacin 82.4%; Kuwait: both 98.7%). Susceptibility was overall >91.2% (CLSI) except for ampicillin (81.0% Kuwait) and trimethoprim/sulfamethoxazole (47.1% UAE/55.7% Kuwait). EUCAST susceptibility was similar, except for cefuroxime. PK/PD susceptibility was similar to CLSI, but lower for cefaclor, cefuroxime and macrolides. CONCLUSIONS: Pneumococci were susceptible to fluoroquinolones (>98%), amoxicillin and amoxicillin/clavulanic acid (>79%-94%), ceftriaxone and cefotaxime (>73%-94%). Susceptibility was lower to oral/low-dose penicillin (20%-27%), macrolides (33%-51%), tetracyclines (53%-59%) and trimethoprim/sulfamethoxazole (33%-61%). Susceptibility was generally >80% in H. influenzae except for trimethoprim/sulfamethoxazole (47%-56%).

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Torumkuney D, Mokaddas E, Weber S, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Kuwait and the United Arab Emirates: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2025. PMID: 41277344. doi:10.1093/jac/dkaf284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。